A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Gbrcamutation Status

被引：0
|
作者：
Untch, Michael [1 ]
Fasching, Peter Andreas [2 ]
Mclaurin, Kimmie [3 ]
机构：
[1] Helios Klinikum Berlin Buch, Berlin, Germany
[2] Univ Klinikum Erlangen, Frauenklin, Erlangen, Germany
[3] AstraZeneca, Gaithersburg, MD USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
232
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [21] Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors
    Mo, Hanjie
    Renna, Catherine E.
    Moore, Halle C. F.
    Abraham, Jame
    Kruse, Megan L.
    Montero, Alberto J.
    LeGrand, Susan B.
    Wang, Lu
    Budd, G. Thomas
    CLINICAL BREAST CANCER, 2022, 22 (02) : 143 - 148
  • [22] CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset
    Buller, William
    Pallan, Lalit
    Chu, Teresa
    Khoja, Leila
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (08) : 1825 - 1835
  • [23] Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors
    Kanjanapan, Yada
    Anderson, Wayne
    Smith, Mirka
    Green, Jenny
    Chalker, Elizabeth
    Craft, Paul
    CLINICAL BREAST CANCER, 2025, 25 (02)
  • [24] Real-world evidence of CDK4/6 Inhibitor combination effects on assessing outcome with different sequence of treatment among adult patients with HR + and HER2-metastatic breast cancer
    Comis, S.
    Kandasamy, T.
    Wu, C.
    Kumar, S. P.
    Upadhyay, V. P.
    Chhikara, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S365 - S365
  • [25] CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence.
    Fiste, Oraianthi
    Liontos, Michael
    Gavriatopoulou, Maria
    Dimitrakakis, Constantine
    Evangelou, George
    Nikolaidou, Vasiliki
    Kotteas, Elias A.
    Syrigos, Kostas N.
    Dimopoulos, Meletios A.
    Zagouri, Flora
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR +/HER2-Breast Cancer at a Single Cancer Center
    Kovacevic, M. Milovic
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    BREAST, 2023, 68 : S46 - S46
  • [27] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [28] UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
    Gullick, G.
    Owen, C.
    Cook, S.
    Helbrow, J.
    Squires, R.
    Reed, H. M.
    Park, S.
    Weir, E.
    Aquilina, F.
    Webber, N.
    Nye, E.
    Atkinson, C.
    Blair, C.
    Halstead, A.
    Daniels, E.
    Alves, A.
    Chew, S.
    Thomas, W.
    Spensley, S.
    Robinson, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S360 - S360
  • [29] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [30] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
12345